🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — March 09, 2026

Across five SEC 8-K filings in the USA S&P 500 Energy stream (primarily oil/gas refining/production with outliers HOFT/HNRG), dominant themes include proactive debt management via tenders and issuances (OXY, VLO totaling ~$2B in activity) and board enhancements with experienced appointees (PSX, HNRG), signaling governance upgrades amid energy transition. No period-over-period financial trends (YoY/QoQ revenue, margins) or operational metrics reported in these event-driven 8-Ks, but debt actions imply balance sheet optimization potentially lowering interest costs (e.g., OXY retiring high-coupon notes like 6.625%). Sentiments skew positive/mixed (2 positive, 1 mixed, 2 neutral), with high materiality in OXY (8/10) and VLO (8/10). Insider activity absent across filings; no capital allocation (dividends/buybacks), M&A, or ratios detailed. Portfolio-level pattern: 40% of filings highlight debt transactions, suggesting sector-wide deleveraging or refinancing ahead of volatility. Actionable implication: Near-term catalysts around Mar 9-19 settlements could support share prices for OXY/VLO.

4 high priority 1 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 09, 2026

Across 50 SEC filings from diverse sectors mislabeled under S&P 500 Financials stream, dominant themes include mixed financial performance with robust revenue growth in 10/18 companies reporting YoY data (avg +120% e.g., SharpLink +666%, BETA +136%, ARS Pharma product +889% to $72.2M) offset by widening net losses in 12/15 (avg +80% deeper, driven by SG&A/R&D surges up 100-200% like ARS +186% opex). M&A and financing activity surges with 8 deals/placements (e.g., Aureus merger, Bunker Hill C$33.75M raise, Mission Produce S-4), signaling consolidation and capital infusion amid cash burns. Financials subset shines: Tri-County Bank NIM +44bps to 3.40%, NI +31% to $13.7M, ROE +164bps to 9.09%; Alexanders $235M asset sale for $147M gain. Capital allocation favors buybacks/dividends (GLDD $12M repurchases, W&T $0.01/sh div Mar 26, News Corp $1B program). Portfolio implications: Bullish on growth outliers pre-catalysts (international approvals, mergers closing Q2-Q3 2026), bearish on expense bloat; watch SPAC extensions/mergers for dilution risks.

31 high priority 19 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 09, 2026

Across 50 US SEC filings from March 9, 2026, dominant themes include a surge in M&A activity (e.g., Aureus Greenway merger, Lisata acquisition, CACI's $2.6B ARKA buy), biotech clinical and financing momentum (Relmada's 76% CR rate, Korro's $85M PIPE), and extensive leadership transitions (18+ appointments/resignations). Period-over-period trends show biotech cost efficiencies with 4/6 reporting R&D/OpEx cuts of 19-40% YoY (e.g., Boundless Bio -26% R&D Q4, Spruce -40% OpEx FY2025) amid narrowing net losses (-11% to -26% YoY), contrasted by energy firms raising capital amid production upticks (Battalion +1,200 bpd Jan vs Dec). Capital allocation leans toward equity/debt raises ($500M+ aggregate PIPEs/securitizations) and buybacks (Ingram Micro $50M), with positive sentiment in 60% of high-materiality filings (>8/10). Portfolio implications: Biotech overweight for catalysts like Phase 3 trials mid-2026; monitor energy leadership voids (Gulfport CEO exit). Forward catalysts cluster in Q2 2026 (merger closings, tender offers). Overall, actionable bullish tilt in growth sectors despite mixed leadership signals.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 09, 2026

Across 19 filings in the S&P 500 Technology stream (broadly including telecom/IT-adjacent), a dominant theme is neutral proxy solicitations and additional materials for upcoming shareholder meetings, particularly in municipal funds and telecom (e.g., Nuveen urging FOR votes by March 19, 2026; Western Asset and Shenandoah meetings in April), signaling routine governance but potential M&A quorum risks. Financial reporters show mixed period trends: revenue declines averaging -7.6% YoY (RideNow -4.7% Q4/-10.5% FY; CMCT implied softer leasing) offset by EBITDA/FFO resilience (RideNow Q4 +340.9% to $9.7M, FY +40.4%; CMCT FFO improved from $(8.7M) to $(7.1M)). SPAC activity highlights tech upside with dMY Squared boosting PIPE to $111.86M via amendments and new investors, contrasting TETUF's 99.5% YoY asset plunge from redemptions. Positive debt maneuvers like Optimum's $1.657B fiber securitization refinancing at ~5.6-5.9% (vs prior 5.625%) bolster telecom balance sheets, while exec changes (Planet Fitness interim CFO, Lyell permanent CFO, Sun COO) are seamless with reaffirmed guidance. Portfolio-level, 3/5 financial filers exhibit EBITDA gains despite topline weakness, no insider trades noted, and capital allocation leans defensive (redemptions, asset sales); implications favor monitoring March-April catalysts for merger/SPAC votes amid neutral sentiment (12/19 neutral).

16 high priority 3 medium 19 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 09, 2026

Across 15 NASDAQ-100 related filings dated March 9, 2026, dominant themes include urgent proxy solicitations for Nuveen Municipal funds (4/15 filings) pushing for merger approvals by March 19, signaling consolidation in muni high-income space; positive financing and regulatory milestones in telecom/mining (Optimum's $1.657B securitization, TMC's NOAA compliance); mixed REIT results at CMCT with wider Q4 net loss but FFO improvement and $31.2M asset sale; deteriorating SPAC metrics at TETUF with 99.5% YoY asset drop; and executive appointments at Lyell and Sun Communities. Period-over-period trends show deterioration in key metrics like CMCT office leasing down 420bp YoY same-store and TETUF trust assets down 99.6% YoY from redemptions, contrasting with Optimum's debt repayment and CMCT's 19% total NOI growth. Portfolio-level patterns reveal neutral-to-positive sentiment in 10/15 filings, with high materiality events clustering around capital events and governance (proxies, redemptions), implying near-term catalysts from March-April shareholder meetings. Market implications favor monitoring muni fund mergers for arb opportunities and telecom strength amid fiber investments, while flagging SPAC liquidation risks.

11 high priority 4 medium 15 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 09, 2026

Across 50 SEC filings from the USA Dow Jones 30 stream (March 9, 2026), overarching themes include robust M&A and financing activity (e.g., Aureus Greenway merger, multiple PIPEs/securitizations totaling $300M+), mixed earnings with strong revenue growth in travel/defense (avg +25% YoY in 6 reporters) offset by margin compression (avg -150bps in 8 companies) and widening losses in biotech (9/12 reporters). Period-over-period trends show revenue up 15-34% YoY in key Q4/FY2025 reports (Amex GBT +34%, Voyager Tech +24%, 908 Devices +18%), but net losses expanded in 70% of loss-reporting firms (e.g., enGene +21%, Voyager Therapeutics FY -84% wider), alongside positive capital raises extending runways into 2028 (Korro Bio $85M, enGene $149M). Critical developments: 5 mergers/acquisitions, 8 financings/offerings, impairments in 4 firms ($43M+ Universal Logistics), and reiterated/raised guidance in 4 (Amex GBT 19-21% growth, Voyager Tech 35-53%). Portfolio-level patterns reveal sector rotation potential—bullish travel/logistics vs bearish shipping/biotech losses—amid governance shifts (CEO changes, board resignations) signaling transition risks/opportunities. Implications: Favor growth acquirers/financed biotechs with catalysts, avoid impairment-heavy firms; alpha from pre-close M&A and Q1 2026 guidance beats.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 09, 2026

Across 50 SEC filings for March 9, 2026, dominant themes include robust product revenue growth in biotech/pharma (e.g., ARS Pharma +888% YoY product rev to $72.2M) offset by surging expenses and widened losses (avg net loss expansion in 7/12 healthcare firms), SPAC extensions/mergers signaling prolonged deal hunts, and divergent energy results with dredge/oil producers outperforming producers (GLDD rev +16.5% YoY vs W&T -4.5%). Period-over-period trends show 14/25 10-Ks with revenue growth averaging +85% YoY in high-flyers like SharpLink (+666%) and BETA (+136%), but margin compression in 9/15 mixed sentiment firms (e.g., Cross Country operating loss to $84M from $17M) and SPAC cash burns. M&A activity surges with 5 deals (Aureus, Mission Produce, Xanadu), capital raises total >$100M (Bunker Hill C$33.7M, Battalion $15M), and positive guidance in Korn Ferry (Q4 rev $730-750M). Portfolio-level patterns flag healthcare turnaround potential amid commercialization ramps, energy FCF resilience despite price weakness, and SPAC dilution risks. Critical implications: Investors should prioritize firms with narrowing losses (Cumberland -55% YoY) and upcoming catalysts like closings/approvals, while monitoring SPAC liquidations.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 09, 2026

Across 50 diverse SEC filings labeled under S&P 500 Consumer Discretionary (though spanning energy, REITs, services, industrials, and CEFs), overarching themes reveal mixed financial performance with 7 key companies posting YoY revenue growth averaging +24% (e.g., FuelCell +61%, LifeMD +25%, GLDD +16.5%) offset by 6 declines averaging -9% (e.g., Franklin Street -10.8%, FreightCar -10%, Fluent -18% FY), alongside frequent leadership transitions and capital return initiatives. Margin trends show outliers like FreightCar (+260bps to 14.6%) and LifeMD gross margin to 87%, but compressions in W&T EBITDA (-15.6%) and Fluent Owned revenue (-44%). Critical developments include Bright Horizons' $600M buyback authorization, Franklin Street's dividend suspension amid occupancy drop to 68.9%, and debt paydowns (Amplify full repayment, GLDD long-term debt -15.6% to $378M). Portfolio-level patterns highlight cash strength (LifeMD $36.8M no debt, FuelCell $379.6M) contrasting FCF weakness (W&T to $1.5M, Amplify FY -$16.1M), with forward guidance mixed (FreightCar FY26 rev $500-550M up mid-point, LifeMD Q1 EBITDA loss $4-5M). Upcoming March-April 2026 shareholder meetings cluster as catalysts, while insider activity is sparse (minor Bunker Hill participation). Market implications favor selective longs in growth/margin expanders and shorts on deteriorating operations, prioritizing capital allocators amid volatility.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 09, 2026

In the S&P 500 Healthcare stream, biotechs like Editas, Spruce, Protagenic, Anixa, MBX, Pulse, and Dare demonstrate aggressive cost discipline with R&D expenses down 29-58% YoY across 5/7 firms, narrowing net losses 19-36% YoY and extending cash runways into 2027, amid pipeline advancements including Phase 3 initiations and BLA filings. Large providers Abbott, Humana, and UnitedHealth show capital raising via $1B+ debt issuances and conference participation, signaling M&A and strategic discussions. Positive clinical data highlights include Pulse's 74% nodule volume reduction (15-22 months post-treatment) and Editas' >90% LDL-C cuts preclinical. Cross-sector filings reveal bank profitability surges (e.g., Financial Institutions NI +170% YoY, ROAE 12.49%) and mixed retail/energy trends, but healthcare outliers shine with margin-neutral cost cuts vs. broader compression. Forward catalysts cluster mid-2026 (IND/BLA/Phase 3), positioning biotechs for alpha amid 4/37 mixed sentiment filings. Overall, healthcare portfolio trend: 6/10 key firms improved losses YoY despite revenue softness, implying resilient cash management but binary pipeline risks.

21 high priority 16 medium 37 total filings
· daily

Global High-Priority Regulatory Events — March 09, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include surging M&A/takeover activity (e.g., Aureus Greenway-Autonomous Power merger, Mission Produce-Calavo acquisition), multiple Indian insolvencies (JCT Ltd, Unitech International, Jhaveri Credits), SPAC extensions amid delays, and mixed 10-K results with healthcare/biotech showing volatility. Period-over-period trends reveal revenue growth in outliers like Cumberland Pharma (+17.6% YoY to $44.5M), 908 Devices (+17.7% to $56.2M), SharpLink Gaming (+666% to $28.1M), and Tri-County Financial (+3.7% assets, +31% net income), contrasted by sharp declines in Cross Country Healthcare (-21.6% revenue, net loss to $95M), Cartesian Therapeutics (-93% revenue), and ARS Pharma (-5% total revenue despite product +). RBI data signals tight liquidity with net absorptions of ₹247k Cr (Mar 7) and ₹241k Cr (Mar 8), below CRR needs. Critical implications: M&A offers takeover premiums and catalysts, insolvencies flag distress selling opportunities, SPACs risk liquidation, while capital raises (Battalion $15M, Bunker Hill C$34M) bolster balance sheets. Portfolio-level: 7/15 10-Ks mixed sentiment with average revenue +18% in winners but losses widening 50-100% in losers; healthcare shows 5/10 margin pressures from impairments.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 09, 2026

The IPO Pipeline stream reveals a diverse set of filings dominated by merger-related S-4s (Mission Produce/AVO acquiring Calavo, Stock Yards/SYBT merging with Field & Main) and S-1s including a post-bankruptcy shelf (Wolfspeed/WOLF), a high-debt IPO candidate, and a new SPAC (West Enclave). Period-over-period trends are sparse but highlight outlier strength in the unknown IPO candidate with operating cash flows surging 118% YoY to $480M in 2025 despite debt service outflows rising 72% YoY to $549.2M (68% of op cash). Mixed/neutral sentiments prevail amid prominent risk disclosures, shareholder approvals, and dilution potentials. Overarching themes include M&A as an IPO alternative, persistent leverage concerns (e.g., $3.98B debt in IPO candidate vs. SPAC's clean $100M raise), and post-reorg activity signaling stabilization. Market implications point to arbitrage opportunities in mergers, caution on leveraged IPOs, and watch for SPAC catalysts in LatAm-focused deals. Portfolio-level, 3/5 filings emphasize special meetings and approvals as near-term catalysts.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — March 09, 2026

Across 50 US SEC filings for FY2025 and early 2026, mixed sentiment prevails in 40+ cases, reflecting revenue volatility amid cost controls narrowing losses in biotechs (avg net loss improvement ~25% YoY in 15/20 biotechs) but widening in others due to impairments (e.g., $616M crypto losses at SharpLink). Revenue trends show stark divergence: explosive growth in select biotechs/pharma (Zevra +350% YoY, Cumberland +17.6%) contrasted by declines in healthcare staffing (-21.6% Cross Country), diagnostics (-38% OraSure), and manufacturing (-12% 3D Systems). Financials exhibit resilience with NIM expansion (Tri-County +44bps, Heritage +31bps) and ROE gains (Tri-County +1.64pp), while SPACs (8 filings) uniformly report trust interest-driven net income (avg +$4M YoY). Impairments aggregate >$2B (e.g., NET Power $1.5B, Repay $242M), signaling overvalued assets, but cash raises bolster biotechs (e.g., enGene +$151M). Capital allocation leans conservative: dividend cuts (Tiptree -51%, Caseys up 14%) and buybacks absent; M&A limited. Portfolio implication: Biotech turnarounds and regional banks offer alpha, avoid impairment-heavy cyclicals amid 2026 policy risks (EVgo OBBBA).

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 09, 2026

Across 32 DEF 14A proxy statements, the dominant theme is routine governance with 28/32 filings neutral in sentiment, focusing on director elections, auditor ratifications (e.g., PwC, Deloitte across multiple), and advisory say-on-pay votes, signaling stable board continuity amid no widespread executive pay controversies. A cluster of 13 closed-end funds (Flaherty & Crumrine, Western Asset) shows highly concentrated ownership via Cede & Co. (98-99.97%) and low director/officer holdings (<1%), indicating institutional dominance but limited insider alignment. Limited period-over-period data reveals outliers like Deluxe Corp's 10% YoY growth in Payments/Data segments (to 47% of revenue from 43%), +6% adjusted EBITDA, +10% adjusted EPS, and FCF exceeding $100M target early, reducing leverage to 3.2x; Citizens Financial Group reported top peer TSR in 2025 with $226.4B assets. Mixed sentiments in 4 filings highlight risks in SPACs (5th extension), biotechs (NeuroOne reverse split for Nasdaq compliance, Moleculin 129% dilution from warrants), tempering portfolio optimism. No insider trading activity or capital allocation changes (dividends/buybacks) disclosed across filings, with forward-looking catalysts centered on April 2026 annual meetings (15+ events). Overall, low materiality (avg 5.6/10) suggests muted near-term volatility, but monitor biotech/SPAC dilutions and governance votes for alpha.

32 high priority 32 total filings
· daily

US Executive Officer Management Changes SEC — March 09, 2026

Across 34 SEC filings on USA Executive & Director Changes from March 9, 2026, the dominant theme is proactive board expansions and executive appointments (18 instances, e.g., Phillips 66 added 2 independent directors, FTI named experienced CFO Angela Nam), signaling strengthened governance amid growth phases, contrasted by 12 departures (7 planned retirements like West Pharma CEO Eric Green H2 2026, 5 sudden like Gulfport CEO John Reinhart). Positive sentiment prevails in 14/34 filings (41%), particularly biotech/pharma (Zevra revenue +351% YoY to $106.5M, Boundless R&D -26% YoY to $9.8M Q4), while mixed/neutral in energy transitions. Period trends show cost discipline (Boundless op ex -23% YoY Q4) and revenue surges (FTI FY25 $3.8B, Zevra Q4 +184% YoY), with reaffirmed guidance in West Pharma/Planet Fitness indicating stability. No widespread insider selling; equity grants/bonuses (e.g., Alpha Omega 220% CEO max bonus) reflect alignment. Sector patterns: Energy leadership churn (4/34 filings), biotech hiring for trials/growth. Implications: Bullish for continuity hires, monitor sudden exits for volatility; portfolio-level alpha in pharma turnarounds.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 09, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive capital raising via PIPEs ($85M Korro, $30M MGNC commitment), ATMs ($100M enGene), private placements ($15M Battalion, $11M Envirotech), and debt refinancings/securitizations ($1.6B Optimum, $900M Genesis revolver), signaling liquidity crunches or preemptive balance sheet fortification amid potential distress. Sparse period-over-period data reveals cost discipline in biotech (Spruce opex -40% YoY to $36.5M, net loss improved 26% to $39M) and operational upticks (Battalion oil prod +1,200 bpd Jan vs Dec), but tightening credit covenants (ProFrac availability cut to $275M, min liquidity $45M) and Nasdaq warnings (Cypherpunk < $1 bid 30 days) underscore distress risks. Direct bankruptcy activity limited to TPI Composites' Ch11 asset sale ($20M), with forbearance extensions (Cannabist to Mar 17) and collateral pledges (Jaguar $10.8M note) as red flags. M&A/asset sales (Lisata acquisition $5/share + CVR, Alexanders $235M property) provide cash influxes, while buybacks (United Therapeutics $2B, SLM $200M ASR) reflect conviction in non-distressed names. Portfolio-level: 18/50 filings involve equity dilution, 12 credit amendments/refis (mostly neutral-positive), implying sector-wide deleveraging but vulnerability to covenant breaches; opportunities in post-sale rebounds, risks in biotech trial failures.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 09, 2026

Three US-listed companies (Longeveron Inc., Cypherpunk Technologies Inc., CIMG Inc.) disclosed critical Nasdaq listing compliance issues on March 3-9, 2026, signaling heightened regulatory risks in the 'USA Trading Suspensions' stream, with no offsetting positive financial trends, period-over-period comparisons, or operational metrics provided across filings to mitigate concerns. Overarching themes include audit committee deficiencies, prolonged sub-$1 bid prices, and outright delisting notices, all carrying high materiality (7-10/10) and predominantly negative-to-bearish sentiment, pointing to potential trading halts, delistings, and liquidity erosion for small-cap names. No YoY/QoQ revenue growth, margin expansions, or positive insider activity disclosed; instead, forward-looking cure periods (up to 360 days) offer slim windows for remediation without guarantees. Portfolio-level pattern: 3/3 companies face Nasdaq rule violations (audit independence, bid price, listing standards), a cluster suggesting broader small/micro-cap vulnerability amid market pressures. Critical implications: Immediate avoidance for long positions, short opportunities pre-delisting, and watch for suspension catalysts. Newly published filings (first 2) amplify urgency versus prior CIMG coverage.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 09, 2026

The 34 filings in the 'USA Board Room Changes' stream reveal a surge in C-suite and board transitions, with 22 CEO/CFO/COO appointments or departures and 12 board additions/resignations, signaling strategic realignments amid growth phases for biotechs and energy firms. Positive sentiments dominate (14/34 filings), driven by experienced hires like FTI Consulting's Angela Nam (scaled revenues 3.5x at prior role) and Mesa Labs' Siddhartha Kadia ($2B business oversight), while mixed/neutral tones accompany sudden exits like Gulfport Energy's CEO Reinhart (materiality 9/10). Period-over-period trends show biotech outperformance: Zevra Therapeutics revenue +351% YoY to $106.5M, Boundless Bio expenses -19% FY YoY with $108M cash to H2 2028; energy firms reaffirm strategies post-changes. No widespread insider selling detected, but capital allocation stable with reaffirmed guidance (Planet Fitness, West Pharma). Portfolio-level pattern: 70% of high-materiality (7+/10) changes are positive/neutral, implying low disruption risk but watch for CEO searches in energy/consulting. Overall, bullish for hires enhancing execution in scaling firms, bearish for leadership vacuums in mature players.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — March 09, 2026

The 14 filings reveal a surge in US M&A and SPAC activity on March 9, 2026, with 10 SPAC-related events dominating (mergers, extensions, IPO upsizes), signaling robust blank-check dealmaking amid energy, AI, and defense sectors. Key completions include Presidio Production's business combination with $87.5M PIPE and $125M preferred, CACI's $2.6B ARKA acquisition enhancing EO/IR capabilities, and MiniMed's $538M IPO proceeds post-Medtronic spin-off. Positive sentiment prevails in 11/14 filings (79%), with total announced/closed deal values exceeding $3.5B (CACI $2.6B, Calisa $180M, Presidio $212.5M PIPE+pref, MiniMed $538M). No broad period-over-period financial declines noted, but SPAC extensions (Aquaron $16K note, Ribbon $600K note) indicate deadline pressures without redemptions flagged. Mixed promo in Pelican/Greenland adds hype to energy exploration, while Trailblazer's Nasdaq non-compliance poses isolated delisting risk. Portfolio trend: SPAC de-SPACs accelerating (3 announced/closed vs prior briefs), favoring liquidity events and sector rotation into geothermal/AI/oil.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 09, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout revenue growth in biotech/pharma (e.g., ARS Pharma product revenue +890% YoY to $72.2M, Cumberland Pharma +17.6% to $44.5M) offset by widening losses and expense surges in 7/15 key 10-Ks; energy firms like W&T Offshore (-4.5% revenue YoY) and Sphere 3D (-32.5%) show declines amid commodity pressures, while SPACs dominate with 8+ merger extensions/announcements. Period-over-period trends highlight revenue expansion averaging +50% YoY in high-growth niches (BETA Tech +136%, SharpLink +666%) but margin compression and net losses in 12/20 metric-rich filings (avg net loss expansion +150%). M&A activity surges with deals like Aureus Greenway/Autonomous Power and Mission Produce/Calavo, alongside financings totaling $100M+ (e.g., Bunker Hill C$33.8M). Capital allocation leans toward debt reduction (GLDD -15.6% long-term debt) and buybacks (News Corp $1B program, GLDD $12M repurchases), but insider activity is absent across filings. Forward-looking catalysts cluster in Q1-Q2 2026 (e.g., FAA certifications, drug approvals, closings), signaling portfolio rotation opportunities from underperformers like Cross Country (-21.6% revenue) to outperformers like Great Lakes Dredge (+16.5% revenue, +28.4% NI). Overall, bullish on select biotech/industrials amid SPAC consolidation, cautious on healthcare staffing and E&P.

31 high priority 19 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 08, 2026

GardaWorld Federal Services LLC secured a $313.4M DHS/ICE delivery order for renovating and operating a detention facility in Surprise, AZ, with ceiling potential of $704.1M via options, signaling robust demand for private infrastructure in immigration enforcement. This firm fixed-price award to the BC Partners-backed firm highlights sector tailwinds amid rising detention needs. Key risks include cost overruns and execution delays, but option exercises could drive 2.2x revenue upside by 2029.

1 total filings